VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister. The company stated it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during the transition. For more details, the full press release is available at https://nnw.fm/BjjY6.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC® is a registered trademark of VERAXA Biotech GmbH.
The appointment of an interim CFO marks a strategic step as VERAXA seeks to strengthen its financial leadership during a pivotal growth period. The company’s focus on antibody-based therapeutics positions it in a competitive biotech landscape, and a stabilized finance function is critical for supporting ongoing clinical development and potential partnerships. Investors and industry observers will be watching for the permanent CFO appointment, which could signal the company’s readiness for expansion. The latest news and updates relating to VRXA are available in the company’s newsroom at http://nnw.fm/VRXA.
